Pharvaris added positive phase III clinical data showing its oral bradykinin B2 receptor agonist deucrictibant is effective in preventing hereditary angioedema (HAE) attacks, building on earlier results for acute attacks. The company said the updated readout strengthens its overall clinical package as it prepares regulatory next steps. The news comes with the FDA decision timeline still pending, making the dataset part of the last mile for a potential approval pathway. In HAE, where attacks can be life-altering and costly, improved prevention data can be pivotal for labeling and treatment positioning. For biotech developers, the case illustrates how adding prevention outcomes can shift how payers and clinicians evaluate oral options versus existing therapies. Investors will likely watch how Pharvaris frames benefit-risk and patient-reported impact, since prevention efficacy often becomes the central value proposition.